BiotechTube
Home/Quince Therapeutics/David Lamond
DL

David Lamond

Board of Directors, President of En Pointe, LLC

Quince Therapeutics

Therapeutic Areas

Rare DiseasesNeurodegenerativeInflammatory

Quince Therapeutics Pipeline

DrugIndicationPhase
eDSP (EryDex)Ataxia-Telangiectasia (A-T)Phase 3

Leadership Team at Quince Therapeutics

DT
Dirk Thye, M.D.
Chief Executive Officer, Chief Medical Officer, and Board Member
CR
Charles Ryan, J.D., Ph.D.
President
BH
Brendan Hannah, M.B.A.
Chief Operating Officer and Chief Business Officer
GM
Giovanni Mambrini, MSc
Chief Technology Officer
CS
Christopher Senner
Board of Directors, Chief Financial Officer of Exelixis
View full Quince Therapeutics profile